Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to confirm the efficacy and safety of perampanel compared to placebo in patients with refractory partial-onset seizures


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT01618695
Study type Interventional
Source Eisai Inc.
Contact
Status Completed
Phase Phase 3
Start date May 15, 2012
Completion date May 28, 2020

See also
  Status Clinical Trial Phase
Completed NCT00232596 - Retigabine (Adjunctive Therapy) Efficacy and Safety Study for Partial Onset Refractory Seizures in Epilepsy Phase 3
Recruiting NCT04015141 - A Study to Evaluate Efficacy and Safety of Perampanel Administered as an Adjunctive Therapy in Pediatric Participants With Childhood Epilepsy Phase 2
Completed NCT01832038 - Study to Evaluate the Safety, Tolerability, and Efficacy of Long-term Adjunctive Therapy With Lacosamide in Adults With Partial-onset Seizures Phase 3
Completed NCT02192814 - Open-label Study to Evaluate the Safety and Tolerability of iv Lacosamide in Japanese Adults With Partial-onset Seizures Phase 3
Completed NCT00235755 - Retigabine Efficacy and Safety Trial for Partial Onset Refractory Seizures in Epilepsy Phase 3
Completed NCT02736162 - Study to Investigate Dosage, Efficacy, and Safety of Perampanel Given as Monotherapy in Patients With Epilepsy N/A
Completed NCT02124564 - A Trial to Evaluate the Long Term Safety and Tolerability of Lacosamide Taken as Monotherapy in Adults With Partial-onset Seizures Phase 3
Completed NCT04230044 - A Study to Evaluate the Safety and Efficacy of Fycompa® (Perampanel) as Add-on Therapy in Participants With Epilepsy